Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.
Importance Rank:
1
Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.